Responses

Download PDFPDF
Research paper
The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy—an open-label, prospective, randomised controlled multicenter study
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Re:Protocol violations and conclusions
    • Felix Rosenow
    • Other Contributors:
      • Carmen Schade-Brittinger, Nicole Burchardi, Philipp S Reif

    We would like to thank Mr Rajendran his detailed and elaborate comment regarding our trial on the initial monotherapy of epilepsy with levetiracetam or lamotrigine (Rosenow et al JNNP 2012) . It is always a good sign when a clinical study finds the interest not only of those already actively contributing to a field of research but also of junior colleagues which have not previously published in the area of clinical epil...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Protocol violations and conclusions
    Sir, The paper by Rosenow et al1 made interesting reading. However, there are few concerns with respect to the conclusions of the study. The study tested for superiority of levetiratecam over lamotrigine with seizure free interval in the first 6 weeks of the trial as the primary endpoint. Assuming a clinically relevant difference of 15% between the groups, the authors estimated a sample size of 183 patients to achieve power o...
    Show More
    Conflict of Interest:
    None declared.